Buradasınız

Anasayfa » Content

A SHORT REVIEW ON ANTIDIABETIC ACTIVITY OF BITTER GOURD

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2013

Key Words:

Author Name
Abstract (2. Language): 
Diabetes is the metabolic disorder occurs due to the defects of Insulin in secretion and/or insulin sensitivity of tissue. Most common type-2 diabetes linked to high consumption of caloric rich diet, obesity, and secondary life style and it is associated with complication like oxidative stress. Synthetic hypoglycemic agent can be used in treatment but it have the undesirable effects like hypoglycemia, anorexia, brain abnormality and fatty liver. So it is the need of recent to use the natural product which has less or no undesirable effect. Bitter gourd (momordica charantia) have antidiabetic activity. Beside this effect it also have anticancer activity. The constituents of bitter gourd, vicine, charantin and polypeptide-p have the antidiabetic effect where as steroidal saponin have sugar lowering effect.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-short-review-antidiabetic-activity-bitter-gourd.pdf
  • 4
333
336
  • English

REFERENCES

References: 

1. Lanza RP, Ecker DM, Kuhtreiber WM, Marsh JP, Ringelling J and Chick WL. Transplantation of islets using microen-capsulation: study in diabetic rodents and dogs. J MOL med(2001); 77:206-10.
2. Word Health Oraganization. Report of a WHO consultation: Defination, diagnosis and classification of diabetes mellitus and its complication. The organization, geneva(1999); 20: 1183-97.
3. E. Wright, JL Scism-Bacon and LC Glass.(2006) oxidative strss in type-2 diabetes: Role of fasting and postprandial glycemia, International journal of clinical practice. 60(3):308-314.
4. Jung M, Park M, Lee HC, Kang YH, Kang ES, Kim SK. current medicinal
chemistry(2006); 13:1203-1218.
5. Swanston flat SK, Day C, Bailey CJ, flat
RR. Diabetologia (1990); 33:462-464.
6. WHO expert committee on diabetes mellitus second report(1980)Technical report series 646,world health organization;geneva.61.
7. Som NS, Praveen V, Shoba S, Radhey S, Kumria MML, Rangnathan S, Sridhran K. J.
ethnopharmacol(2001); 76:269-277.
8. Yaryura-Tobias JA, Pinto A , Neziroglu F. Anorexia nervosa, diabetes mellitus, brain atropy and fatty liver Int, J. Etiol.(2001)
30:350-3
9. Prince SMP, Kamalakkannan N. J BIochem-mol Toxicol (2006); 20:96-102.
10. Memorial sloan-kettering cancer, Bitter melon. Available at: http:/www.org/mskcc/html/69.138.cfm. Accesed jan 2, (2011).
11. Grover JK, Yadav SP:
Pharmacological action and potencial uses of momordica charantia: A review J
Ethnopharmacol(2004); 19:123-132.
12. Basch E, Gabardi S, Vlbricht C: Bitter melon(momordica charantia):A review of a efficacy and safety. Am J Health sys pharm
(2003); 60:356-359.
13. Gadang V, Gilbert W, Hettiararchchy N, Horax R, Katwa L, Devareddy L:Dietary bitter melon seed increase peroxisome proliferator-activated receptor-gamma gene expression in adipose tissue, down-regulates the nuclear factor-kappa B expression, and alleviates the symptoms
Available Online at www.ijprbs.com
Review Article CODEN: IJPRNK
Jatin Panara, IJPRBS, 2013; Volume 2(4): 333-336
ISSN: 2277-8713 IJPRBS
associated with metabolic syndrome J med food(2011); 14:86-93
14. Raman A, Lau C. Antidiabetic properties and phytochemistry of momordica charantia L.(cucurbitaceae).phytomed (1996) 2:349¬62.
15. Yeh G, Eisenberg D, Kaptchuk T, Phillips R. Systemic review of hearbs and dietary
supplements for glycemic control in diabetes care(2003); 26(4):1277-1294.
16. Srivastava Y, Venkatakrishna Bhatt H, Verma Y, Venkaiah K, Raval BH(1993);Antidiabetic properties of momordica charantia extract: an experimental and clinical evaluation. phytotherapy research 7(4):285.

Thank you for copying data from http://www.arastirmax.com